Loading market dashboard
Agenus Inc.
AGENHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2026 and enter the 16-digit control number found in their proxy mate.
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Agenus: Weighing The Clinical Progress Against The Company's Cash
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology images in patients treated with botensilimab (BOT) plus balstilimab (BAL), Agenus' investigational next-generation multifunctional, Fc-enhanced anti-CTLA-4 and anti.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ASCO2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus' multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The full dataset wi.
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled “A phase 1b study of botensilimab and balstilimab in treatment-refractory h.
Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, and provided an operational update on botensilimab plus balstilimab (BOT+BAL), the Company's lead clinical program and one of the most clinically advanced next-generation CTLA-4/PD-1 combinations in development. The first quarter marked a transition from foundation-building to execution for BOT+BAL. Physician engageme.
Here is how Agenus (AGEN) and Align Technology (ALGN) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026. Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program. About.
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
HSIC heads into Q1 earnings results with steady estimates, a 5.1% revenue growth outlook and strength across distribution, specialty products and tech.
CI approaches Q1 results with strong pharmacy growth but a steep premium drop, as estimates point to mixed year-over-year performance.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab (BOT), alone or in combination with balstilimab (BAL), have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago, Illinois. The accepted abstracts reflect continued progress of Agenus' botensilimab and balstilimab immunotherapy program ac.
LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)---- $AGEN #AAC--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus' global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Ef.
Here is how Agenus (AGEN) and Apyx Medical (APYX) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, MiNK's allo-iNKT cell therapy, ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer.
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Agenus Inc. (NASDAQ: AGEN - Get Free Report) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.67 and traded as high as $4.30. Agenus shares last traded at $4.15, with a volume of 1,296,172 shares. Analysts Set New Price Targets AGEN has been the subject
Agenus (AGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Agenus (AGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is how Agenus (AGEN) and Ensign Group (ENSG) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, CA. The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus' immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC).
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations. Analyst Ratings This is a summary of recent
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Company's patient access programs, development across tumor types, and key priorities for 2026. The session will be moderated by Garo H. Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab (BAL) in first-line microsatellite stable colorectal cancer (MSS CRC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 18–23 in San Diego, CA. The BBoPCO study (Botensilimab and Balstilimab Optimization.
Agenus (AGEN) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $1.27 per share. This compares to a loss of $2.04 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program across patient access, clinical execution, and commercial readiness. BOT+BAL is a next-generation CTLA-4/PD-1 immunotherapy combination which activates both innate and adaptive immunity and has demonstrated immunotherapy benefit in tumors historica.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform.
